The docket for the FDA's most recent efforts to address the off-label question drew dozens of comments, many of which were at least modestly supportive of the changes in the agency's stance. However, two trade associations opined that the FDA is too pessimistic about the impact of a less stringent standard for off-label communication on the incentives to study those off-label uses.